País: Canadá
Língua: inglês
Origem: Health Canada
HYDROCHLOROTHIAZIDE; CANDESARTAN CILEXETIL
JUBILANT GENERICS LIMITED
C09DA06
CANDERSARTAN AND DIURETICS
25.0MG; 32.0MG
TABLET
HYDROCHLOROTHIAZIDE 25.0MG; CANDESARTAN CILEXETIL 32.0MG
ORAL
30/90/500/1000
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0244181003; AHFS:
APPROVED
2014-07-23
_Candesartan Cilexetil and Hydrochlorothiazide _ _Page 1 of 39 _ PRODUCT MONOGRAPH PR CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE Candesartan Cilexetil / Hydrochlorothiazide Tablets 16 mg / 12.5 mg and 32 mg / 25 mg Angiotensin II AT 1 Receptor Blocker + Diuretic MANUFACTURER: Jubilant Generics Limited 1-A, Sector -16A, Institutional Area, Noida -201301, Uttar Pradesh, India DATE OF REVISION: April 7, 2020 DISTRIBUTOR: Septa Pharmaceuticals Inc. 7490 Pacific Circle, #1 Mississauga, ON L5T 2A3 SUBMISSION CONTROL NO: 237757 _Candesartan Cilexetil and Hydrochlorothiazide _ _Page 2 of 39 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE....................................................................................... 3 CONTRAINDICATIONS ............................................................................................................ 3 WARNINGS AND PRECAUTIONS .......................................................................................... 4 ADVERSE REACTIONS .......................................................................................................... 10 DRUG INTERACTIONS ........................................................................................................... 15 DOSAGE AND ADMINISTRATION ....................................................................................... 20 OVERDOSAGE ......................................................................................................................... 22 ACTION AND CLINICAL PHARMACOLOGY ..................................................................... 22 STORAGE AND STABILITY .................................................................................................. 26 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................... 26 PART II: SCIENTIFIC Leia o documento completo